Acelyrin Raises $300 million Series C

Acelyrin raised $300M in Series C financing led by Various. AI-accelerated late-stage asset acquisition and development. The new capital is framed around Advance izokibep through Phase 3 for PsA and uveitis indications.

What it does

AI-accelerated late-stage asset acquisition and development. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.

Traction

Izokibep advances in Phase 2 for psoriatic arthritis and uveitis. Management framed the new capital around Advance izokibep through Phase 3 for PsA and uveitis indications.

Trend impact

Late-stage biotech competing with large pharma for in-licensing deals. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.

Funding history

• December 1, 2022 · Series C · $300 million · Various

Products & services

• Healthcare & Life Sciences workflow monitoring tied to the funding announcement
• Customer-facing product described on the company website
• Operational tooling for healthcare & life sciences teams
• Data capture and reporting across core business processes
• Team expansion support funded by the latest round